OnKure Therapeutics, Inc. Price & Performance (OKUR)

OnKure Therapeutics is set to make significant strides in 2025, with updates on its PIKture-01 trial expected in the second half of the year. The company plans to reveal additional data on OKI-219 and announce a new pan-mutant inhibitor program in Q2, aiming to solidify its position in oncology.12

H.C. Wainwright lowered OnKure Therapeutics' price target to $34, citing ongoing clinical trials and financial performance. Despite this, the firm maintained a Buy rating, reflecting confidence in OnKure's lead candidate, OKI-219. Analysts highlight its potential to address tolerability issues in the PI3Kα inhibitor space.23

OnKure Therapeutics has garnered attention following analyst updates and upcoming investor conference presentations. With its OKI-219 program progressing and new developments anticipated in 2025, the company is positioning itself as a key player in precision oncology. Analysts suggest monitoring its clinical trial advancements.45